Table 1 Chemotherapy regimens
From: Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
Reginmen | Drug types | Amounts | Treatment courses |
|---|---|---|---|
AC-P/T | Adriamycin | 60 mg/m2 | q3w x 4 |
Cyclophosphamide | 600 mg/m2 | q3w x 4 | |
Paclitaxel | 175 mg/m2 | q3w x 4 | |
Docetaxel | 75 mg/m2 | q3w x 4 | |
EC-P/T | Epirubicin | 100 mg/m2 | q3w x 4 |
Cyclophosphamide | 600 mg/m2 | q3w x 4 | |
Paclitaxel | 175 mg/m2 | q3w x 4 | |
Docetaxel | 75 mg/m2 | q3w x 4 | |
TAC/PAC | Docetaxel | 80 mg/m2 | q3w x 6 |
Paclitaxel | 75 mg/m2 | q3w x 6 | |
Adriamycin | 50 mg/m2 | q3w x 6 | |
Cyclophosphamide | 600 mg/m2 | q3w x 6 | |
TEC/PEC | Docetaxel | 80 mg/m2 | q3w x 6 |
Paclitaxel | 75 mg/m2 | q3w x 6 | |
Epirubicin | 50 mg/m2 | q3w x 6 | |
Cyclophosphamide | 600 mg/m2 | q3w x 6 |